The role of the pharmacist in the management of type 2 diabetes: current insights and future directions

Jeffery David Hughes, Yosi Wibowo, Bruce Sunderland, Kreshnik Hoti, Jeffery David Hughes, Yosi Wibowo, Bruce Sunderland, Kreshnik Hoti

Abstract

Type 2 diabetes is a chronic disease occurring in ever increasing numbers worldwide. It contributes significantly to the cost of health globally; however, its management remains in the most part less than optimal. Patients must be empowered to self-manage their disease, and they do this in partnership with health care professionals. Whilst the traditional role of the pharmacist has been centered around the supply of medicines and patient counseling, there is an evergrowing body of evidence that pharmacists, through a range of extended services, may contribute positively to the clinical and humanistic outcomes of those with diabetes. Further, these services can be delivered cost-effectively. This paper provides a review of the current evidence supporting the role of pharmacists in diabetes care, whilst providing a commentary of the future roles of pharmacists in this area.

Keywords: benefits; cost-effectiveness; glycemic control; interventions; outcomes; pharmacy.

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Model of care for T2DM in primary care. Note: Data from references 1 and 13–15. Abbreviation: T2DM, type 2 diabetes mellitus.

References

    1. American Diabetes Association Standards of medical care in diabetes - 2013. Diabetes Care. 2013;36(Suppl 1):S11–S66.
    1. Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes mellitus in children and adolescent. J Pediatr. 2005;146(5):693–700.
    1. American Diabetes Association Type 2 diabetes in children and adolescents. Diabetes Care. 2000;23(3):381–389.
    1. International Diabetes Federation IDF Diabetes Atlas. Seventh Edition. 2015. [Accessed October 28, 2016]. Available from: .
    1. World Health Organization Obesity and overweight. Fact sheet [updated June 2016] [Accessed October 28, 2016]. Available from:
    1. World Health Organization Diabetes Fact sheet [reviewed November 2016] [Accessed November 27, 2016]. Available from:
    1. Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes. 2008;26(2):77–82.
    1. Kocur I, Resinkoff S. Visual impairment and blindness in Europe and their prevention. Br J Ophthalmol. 2002;86(7):716–722.
    1. Diabetes Australia Diabetes in Australia. 2015. [Accessed October 28, 2016]. Available from: .
    1. Chloe HM, Mitrovich S, Dubay D, Hayward RA, Krein SL, Vijan S. Proactive case management of high-risk patients with type 2 diabetes mellitus by clinical pharmacist: a randomized controlled trial. Am J Manag Care. 2005;11(4):253–260.
    1. Global pharmacy workforce and migration report: a call for action. 2016. [Accessed October 28, 2016]. Available from: .
    1. Health at a glance 2015. 2015. [Accessed October 28, 2016]. Available from: .
    1. The Royal Australian College of General Practitioners . General Practice Management of Type 2 Diabetes: 2016–18. East Melbourne, Vic: RACGP; 2016. [Accessed December 22, 2016]. Available from: .
    1. Indonesian Society of Endocrinology . Consensus on the Management and Prevention of Type 2 DM in Indonesia. Jakarta: Indonesian Society of Endocrinology; 2011.
    1. Power A, Douglas E, McGregor A, Hudson S. Professional development of pharmaceutical care in type 2 diabetes mellitus: a multidisciplinary conceptual model. Int J Pharm Pract. 2006;14(4):289–299.
    1. Department of Health, WA, Australia . Diabetes Model of Care. Health Networks Branch, Department of Health; Perth, WA, Australia: 2008. [Accessed November 27, 2016]. Available from: .
    1. Helper CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47(3):533–543.
    1. Berenguer B, La Casa C, de la Matta M, Martin-Calero MJ. Pharmaceutical care: past, present and future. Curr Pharm Des. 2004;10(31):3931–3946.
    1. Aguiar PM, Brito Gde C, Lima Tde M, Santos AP, Lyra DP, Jr, Storpirtis S. Investigating sources of heterogeneity in randomized controlled trials of the effects of pharmacist interventions on glycemic control in type 2 diabetic patients: a systematic review and meta-analysis. PLoS One. 2016;11(3):e0150999.
    1. Santschi V, Chiolero A, Paradis G, Colosimo AL, Burnand B. Pharmacist interventions to improve cardiovascular disease risk factors in diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Care. 2012;35(12):2706–2717.
    1. Collins C, Limone BL, Schoole JM, Coleman CI. Effect of pharmacist intervention on glycemic control in diabetes. Diabetes Res Clin Pract. 2011;92(2):145–152.
    1. Wang Y, Yeo QQ, Ko Y. Economic evaluations of pharmacist-managed services in people with diabetes mellitus: a systematic review. Diabet Med. 2016;33(4):421–427.
    1. Al Mazroui NR, Kamal MM, Ghabash NM, Yacout TA, Kole PL, McElnay JC. Influence of pharmaceutical care on health outcomes in patients with type 2 diabetes mellitus. Br J Clin Pharmacol. 2009;67(5):547–557.
    1. Chan CW, Siu SC, Wong CK, Lee VW. A pharmacist care program: positive impact on cardiac risk in patients with type 2 diabetes. J Cardiovasc Pharmacol Ther. 2012;17(1):57–64.
    1. Adibe MO, Ukwe CV, Aguwa CN. The impact of pharmaceutical care intervention on the quality of life of Nigerian patients receiving treatment for type 2 diabetes. Value Health Reg Issues. 2013;2(2):240–247.
    1. Farsaei S, Sabzghabaee AM, Zargarzadeh AH, Amini M. Effect of pharmacist-led patient education on glycemic control of type 2 diabetics: a randomized controlled trial. J Res Med Sci. 2011;16(1):43–49.
    1. Adepu R, Rasheed A, Nagavi BG. Effect of patient counseling on quality of life in type-2 diabetes mellitus patients in two selected South Indian community pharmacies: a study. Indian J Pharm Sci. 2007;69(4):519–524.
    1. Venkatesan R, Devi AS, Parasuraman S, Sriram S. Role of community pharmacists in improving knowledge and glycemic control of type 2 diabetes. Perspect Clin Res. 2012;3(1):26–31.
    1. Correr CJ, Melchiors AC, Fernandez-Llimos F, Pontarolo R. Effects of a pharmacotherapy follow-up in community pharmacies on type 2 diabetes patients in Brazil. Int J Clin Pharm. 2011;33(2):273–280.
    1. Phumipamorn S, Pongwecharak J, Soorapan S, Pattharachayakul S. Effects of the pharmacist’s input on glycaemic control and cardiovascular risks in Muslim diabetes. Prim Care Diabetes. 2008;2(1):31–37.
    1. Jarab AS, Alqudah SG, Mukattash TL, Shattat G, Al-Qirim T. Randomized controlled trial of clinical pharmacy management of patients with type 2 diabetes in an outpatient diabetes clinic in Jordan. J Manag Care Pharm. 2012;18(7):516–526.
    1. Mahwi TO, Obied KA. Role of the pharmaceutical care in the management of patients with type 2 diabetes mellitus. Int J Pharm Sci Res. 2013;4(4):1363–1369.
    1. Chung WW, Chua SS, Lai PS, Chan SP. Effects of a pharmaceutical care model on medication adherence and glycemic control of people with type 2 diabetes. Patient Prefer Adherence. 2014;8:1185–1194.
    1. Berringer R, Shibley MC, Cary CC, Pugh CB, Powers PA, Rafi JA. Outcomes of a community pharmacy based diabetes monitoring program. J Am Pharm Assoc (Wash) 1999;39(6):791–797.
    1. Krass I, Armour CL, Mitchell B, et al. The Pharmacy Diabetes Care Program: assessment of a community pharmacy diabetes service model in Australia. Diabet Med. 2007;24(6):677–683.
    1. Armour CL, Taylor SJ, Hourihan F, Smith C, Krass I. Implementation and evaluation of Australian pharmacists’ diabetes care services. J Am Pharm Assoc. 2004;44(4):455–466.
    1. Fornos JA, Andrés NF, Andrés JC, Guerra MM, Egea B. A pharmacotherapy follow-up program in patients with type-2 diabetes in community pharmacies in Spain. Pharm World Sci. 2006;28(2):65–72.
    1. Wermeille J, Bennie M, Brown I, McKnight J. Pharmaceutical care model for patients with type 2 diabetes: integration of the community pharmacist into the diabetes team - a pilot study. Pharm World Sci. 2004;26(1):18–25.
    1. Cranor CW, Bunting BA, Christensen DB. The Asheville Project: long-term clinical and economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc (Wash) 2003;43(2):173–184.
    1. Bliss EA, Codack H, Boothe J. Diabetes care - an evaluation of a community pharmacy based HbA1c testing service. Pharm J. 2001;267:264–266.
    1. Swain JH, Macklin R. Individualised diabetes care in a rural community pharmacy. J Am Pharm Assoc (Wash) 2001;41(3):458–461.
    1. Hughes J. Final report: Customised education programs for patients with diabetes mellitus - use of structured questionnaires and education modules (DMEP study) Perth: Curtin University of Technology; 2006. [Accessed December 21, 2016]. Available from:
    1. Fera T, Bluml BM, Ellis WM, Schaller CW, Garrett DG. The diabetes ten city challenge: interim clinical and humanistic outcomes of a multisite community pharmacy diabetes care program. J Am Pharm Assoc (2003) 2008;48(2):181–190.
    1. Pinto SL, Bechtol RA, Partha G. Evaluation of outcomes of a medication therapy management program for patients with diabetes. J Am Pharm Assoc (2003) 2012;52(4):519–523.
    1. Krass I, Stephenson S, Thuis U, Hourihan F, Taylor S, Armour C. Increasing adherence to medications through delivery of a disease management service for Type 2 diabetes in community pharmacies. J Soc Admin Pharm. 2002;19(6):211.
    1. Grant RW, Devita NG, Singer DE, Meigs JB. Improving adherence and reducing medication discrepancies in patients with diabetes. Ann Pharmacother. 2003;37(7–8):962–969.
    1. Abduelkarem AR, Sackville MA. Changes of some health indicators in patients with type 2 diabetes: a prospective study in three community pharmacies in Sharjah, United Arab Emirates. Libyan J Med. 2009;4(1):31–36.
    1. Blenkinsopp A, Hassey A. Effectiveness and acceptability of community pharmacy-based interventions in type 2 diabetes: a critical review of intervention design, pharmacist and patient perspectives. Int J Pharm Pract. 2005;13(4):231–240.
    1. Pousinho S, Morgado M, Falcão A, Alves G. Pharmacist interventions in the management of type 2 diabetes mellitus: a systematic review of randomized controlled trials. J Manag Care Spec Pharm. 2016;22(5):493–515.
    1. Omran D, Guirguis LM, Simpson SH. Systematic review of pharmacist interventions to improve adherence to oral antidiabetic medications in people with type 2 diabetes. Can J Diabetes. 2012;36(5):292–299.
    1. Wubben DP, Vivian EM. Effects of pharmacist outpatient interventions on adults with diabetes mellitus: a systematic review. Pharmacotherapy. 2008;28(4):421–436.
    1. Petkova VB, Petrova GI. Pilot project for education of patients with type 2 diabetes by pharmacists. Acta Diabetol. 2006;43(2):37–42.
    1. Bunting BA, Lee G, Knowles G, Lee C, Allen P. The hickory project: controlling healthcare costs and improving outcomes for diabetes using the Asheville project model. Am Health Drug Benefits. 2011;4(6):343–350.
    1. Wertz D, Hou L, DeVries A, et al. Clinical and economic outcomes of the Cincinnati Pharmacy Coaching Program for diabetes and hypertension. Manag Care. 2012;21(3):44–54.
    1. Hendrie D, Miller TR, Woodman RJ, Hoti K, Hughes J. Cost-effectiveness of reducing glycaemic episodes through community pharmacy management of patients with type 2 diabetes mellitus. J Prim Prev. 2014;35(6):439–449.
    1. Twigg MJ, Poland F, Bhattacharya D, Desborough JA, Wright DJ. The current and future roles of community pharmacists: views and experiences of patients with type 2 diabetes. Res Social Adm Pharm. 2013;9(6):777–789.
    1. Dhippayom T, Krass I. Supporting self management of type 2 diabetes: is there a role for the community pharmacist? Patient Prefer Adherence. 2015;9:1085–1092.
    1. Krass I, Mitchell B, Clarke P, et al. Pharmacy diabetes care program: analysis of two screening methods for undiagnosed type 2 diabetes in Australian community pharmacy. Diabetes Res Clin Pract. 2007;75(3):339–347.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する